Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. (Q45376093)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Jean-Christophe Pagès

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

T Lecomte

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

C Villalva

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

C Collin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

A Ferru

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

J M Tourani

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

C Silvain

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

P Levillain

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

L Karayan-Tapon

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

4 January 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

1267-1273

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23293113%20AND%20SRC:MED&resulttype=core&format=json

Global cancer statistics, 2002

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Sensitive sequencing method for KRAS mutation detection by Pyrosequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Comparison of GenFlex Tag Array and Pyrosequencing in SNP Genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Use of pyrosequencing of 16S rRNA fragments to differentiate between bacteria responsible for neonatal sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Comparative analysis of pyrosequencing and QMC-PCR in conjunction with high resolution melting for KRAS/BRAF mutation detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Should oncologists be aware in their clinical practice of KRAS molecular analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Detecting biomarkers with microdroplet technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

RAF/RAS oncogenes and mismatch-repair status

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620

Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS620